<DOC>
	<DOCNO>NCT00003178</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness idarubicin cladribine treat child recurrent acute myeloid leukemia .</brief_summary>
	<brief_title>Chemotherapy Treating Children With Recurrent Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete response rate child primary refractory recurrent acute myeloid leukemia ( AML ) secondary AML treat idarubicin cladribine . ( Refractory AML stratum close 4/3/01 ) ( Secondary AML stratum close 04/02/02 ) - Compare remission reinduction rate child relapse 1 year earlier v 1 year time initial remission . - Determine toxic effect regimen patient population . OUTLINE : Patients stratify accord disease characteristic ( primary secondary acute myeloid leukemia ( AML ) first untreated relapse v primary refractory AML ) . ( Refractory AML stratum close 4/3/01 ) ( Secondary AML stratum close 04/02/02 ) Patients receive idarubicin IV 15 minute day 1-3 , cladribine IV 2 hour day 1-5 , filgrastim ( G-CSF ) subcutaneously begin day 6 continue blood count recover 2 day . Treatment repeat every 3 week 2 course absence disease progression unacceptable toxicity . Patients achieve complete response completion course 1 may proceed chemotherapy bone marrow transplantation discretion protocol investigator . Patients extramedullary disease may receive intrathecal chemotherapy radiotherapy symptomatic site . Patients follow every 3 month 1 year , every 6 month 4 year , annually thereafter . PROJECTED ACCRUAL : A total 51-102 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Acute myeloid leukemia ( AML ) ( FAB M0M7 ) Secondary AML first relapse ( Secondary AML stratum close 04/02/02 ) AML primary induction failure ( Refractory AML stratum close 04/03/01 ) Myelodysplastic syndrome ( MDS ) ( relate Down syndrome ) ( MDS stratum close 04/03/01 ) Extramedullary disease allow Relapse 6 month allogeneic autologous bone marrow transplantation allow PATIENT CHARACTERISTICS : Age : Under 21 diagnosis Performance status : Karnofsky 50100 % ( 10 year ) Lansky 50100 % ( 10 year ) Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 1.5 mg/dL ALT le 3 time normal Renal : Creatinine le 2 time normal Cardiovascular : Shortening fraction great 29 % Ejection fraction great 55 % normal wall motion Other : No uncontrolled infection Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : At least 12 week since prior idarubicin recover At least 2 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>